Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Imfinzi Receives New FDA Indication for Advanced or Metastatic Biliary Tract Cancer

JHOP - October 2022 Vol 12, No 5 - FDA Oncology Update
NEW INDICATIONS

On September 2, 2022, the FDA accelerated the approval of durvalumab (Imfinzi; AstraZeneca), a PD-L1 inhibitor, in combination with gemcitabine and cisplatin, for adults with locally advanced or metastatic biliary tract cancer.

Durvalumab was previously approved for unresectable, stage III non–small-cell lung cancer and for first-line treatment of extensive-stage small-cell lung cancer.

The approval of the new indication was based on results of the randomized, double-blind, placebo-controlled, multiregional TOPAZ-1 clinical trial of 685 patients with histologically confirmed, locally advanced, unresectable or metastatic biliary tract cancer (including 56% patients with intrahepatic cholangiocarcinoma, 25% patients with gallbladder cancer, and 19% with extrahepatic cholangiocarcinoma).

The patients were randomized 1:1 to durvalumab plus chemotherapy or to placebo plus chemotherapy and continued treatment until disease progression or unacceptable adverse events.

The median overall survival was 12.8 months in the durvalumab plus chemotherapy arm and 11.5 months in the placebo plus chemotherapy arm (95% confidence interval, 10.1-12.5). The median progression-free survival was 7.2 months with durvalumab and 5.7 months with placebo. The investigator-assessed overall response rate was 27% with durvalumab and 19% with placebo.

The most common (≥20%) adverse events were fatigue, nausea, constipation, decreased appetite, abdominal pain, rash, and pyrexia.

Related Items
Epkinly FDA Approved for Relapsed or Refractory Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma
Online First published on June 5, 2023 in FDA Oncology Update
Lynparza FDA Approved, in Combination With Abiraterone and Prednisone (or Prednisolone), for Metastatic Castration-Resistant Prostate Cancer With BRCA Mutation
Online First published on June 5, 2023 in FDA Oncology Update
Polivy Received New Indication for First-Line Treatment of Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, and High-Grade B-Cell Lymphoma
Online First published on June 5, 2023 in FDA Oncology Update
Omisirge FDA Approved for Patients with Hematologic Malignancies to Reduce Time to Neutrophil Recovery and Infection
Online First published on May 12, 2023 in FDA Oncology Update
Padcev plus Keytruda Granted Accelerated FDA Approval for Locally Advanced or Metastatic Urothelial Carcinoma
Online First published on April 24, 2023 in FDA Oncology Update
FDA Approved Zynyz for Metastatic or Recurrent Locally Advanced Merkel-Cell Carcinoma
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
FDA Approved Tafinlar plus Mekinist for Pediatric Patients with BRAF V600E Mutation–Positive Low-Grade Glioma
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
FDA Granted Jemperli Regular Approval for dMMR Endometrial Cancer
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
FDA Expanded Eligibility for Verzenio plus Endocrine Therapy in Patients with Early Breast Cancer
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
Trodelvy Now FDA Approved for HR-Positive, HER2-Negative Breast Cancer
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.